WEST PHARMACEUTICAL SERVICES INC

NYSE: WST·Exton, Pennsylvania·

Price
$417.80
Base IV
$120.66

Valuation snapshot

Above bull case

At $417.80, the price is above even our bull case of $164.43.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$120.66
29% of the price · range $81.13–$164.43
Price vs base case
246% above
$417.80 against $120.66
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $81.13 to bull $164.43. Values per share.

Price against each value

Bear case
$81.13
Price 415% above
No growth
…
—
Base case
$120.66
Price 246% above
Researched byClaude Opus 5.5
Valuation Nov 13, 2026 · Price as of Nov 16, 2026How we got here

What does West Pharmaceutical Services do?

West Pharmaceutical Services designs and manufactures primary packaging, containment systems, and drug delivery devices for pharmaceutical and medical device companies to ensure safe drug storage and administration.

It brought in $3.4B of sales in the 12 months to Sep 2026.

Led by Michel Lagarde, President and Chief Executive Officer since 2026. West Pharmaceutical Services Form 8-K (Item 5.02) – Appointment of Michel Lagarde as President and CEO

West NovaPure elastomeric vial stoppersImage: West Pharmaceutical Services
Industry
Healthcare
Based in
Exton, Pennsylvania
Trades on
NYSE as WST

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 19¢ was left as profit after every cost, interest and tax. The biggest cost is running the business, 77¢ of every dollar.

  • Running the business77¢
  • Tax5¢
  • Left as profit19¢
  • Other items after tax came back in+1¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays West Pharmaceutical Services, and for what?

West makes packaging, containers, and delivery devices used with injectable medicines, along with related testing and support services. It also designs and manufactures complex medical and other devices for customers, earning revenue from sales of products and services.

Its customers are pharmaceutical, biotechnology, generic drug, diagnostic, and medical device companies.

  • Proprietary Products

    81%

    Proprietary packaging and drug containment products, delivery devices, integrated systems, and laboratory and technical services.

    West NovaPure elastomeric vial stoppersImage: West Pharmaceutical Services
  • Contract-Manufactured Products

    19%

    Design, manufacture, and automated assembly of customer devices and components, including for pharmaceutical, diagnostic, and medical device uses.

    Cleanroom contract manufacturingImage: West Pharmaceutical Services
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Eschweiler plant — Eschweiler, Germany. West's largest manufacturing plant produces elastomer components for injectable medicines and is one of its high-value packaging component centers of excellence.
  • Damastown facility — Dublin, Ireland. A 165,000-square-foot expansion adds commercial-scale drug handling and automation capacity for high-volume injectable therapies, including GLP-1 treatments.
  • Grand Rapids facility — Grand Rapids, United States. West identifies this contract manufacturing facility as a site for GLP-1 drug-delivery device production.
  • Kinston plant — Kinston, United States. Its elastomer production supports injectable-drug packaging, and West designates it a high-value packaging component center of excellence.
  • Jurong plant — Jurong, Singapore. This high-value packaging component center of excellence provides regional production capacity for West's Asia-Pacific customers.
See them on the globe

2025 Form 10-K

How is the business doing?

Sales grew from $2.1B in 2020 to $3.1B in 2025, about 7% a year.

Running the business leaves about 23¢ of each sales dollar as operating profit, up from 19¢ in 2020.

After paying for its upkeep and new investment, it had $453.4M of cash to spare in the 12 months to Sep 2026.

Sales$3.1B
20162025
Operating margin19%
20162025
Free cash flow$468.9M
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

West says it exists to contain and deliver injectable therapies that improve patients’ lives.

“We contain and deliver injectable therapies that improve patient lives.”

About West: Culture and Values

Who is responsible for the plan?

Roles checked November 13, 2026.

What management says it is working on now:

  • Grow high-value components

    Management cited continued strength in biologics, customer upgrades to higher-value components, and growth in GLP-1 related components as drivers of recent results.

    West Reports Second-Quarter 2026 Results
  • Expand drug handling solutions

    Management described a plan to add more steps for customers, including checking and installing drug cartridges into delivery devices, with the business expected to build over time.

    West Pharmaceutical Services Q2 2026 Earnings Call Transcript
  • Invest in capacity and automation

    Management said it is investing to support organic growth, with particular emphasis on high-value products and finishing processes.

    West Pharmaceutical Services Q2 2026 Earnings Call Transcript
  • Maintain product quality and regulatory readiness

    The company says quality, manufacturing expertise, and regulatory compliance are central to serving customers and delivering products reliably.

    2025 Form 10-K
2026 net sales, 2026
$3.345 billion to $3.380 billion
West Reports Second-Quarter 2026 Results
2026 organic net sales growth, 2026
10% to 11%
West Pharmaceutical Services Q2 2026 Earnings Call Transcript
2026 adjusted diluted EPS, 2026
$8.85 to $9.05
West Reports Second-Quarter 2026 Results
Annex 1 related product mix shift, 2026
200 basis points of revenue growth
West Pharmaceutical Services Q2 2026 Earnings Call Transcript
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is slowing. In Q3 2026 it sold 9% more than a year earlier. The year before, quarters averaged 13%.

Its operating margin is wider than a year ago: 31¢ per sales dollar, against 21¢.

The share price is about where it was in Oct 2026, near $417.80.

Bull $164.43Base $120.66Bear $81.13Oct 30Nov 16 · $417.80
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • Late 2026 into 2027

    Drug handling solutions ramp

    Management said revenue from its drug handling solutions program is expected to build toward the end of 2026 and ramp further into 2027.

    West Pharmaceutical Services Q2 2026 Earnings Call Transcript
  • 2027

    Daikyo license agreements

    The company says certain important product and process licenses expire in 2027; renewal or early termination could affect access to those technologies.

    2025 Form 10-K

Our own estimate moved too: the base case went from $116.16 to $120.66 a share between our last two valuations. The biggest reason: Net sales growth YoY, quarterly moved from an unreported prior value to 8.7%, as reported in WST Q3 2026 earnings release.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Dependence on injectable medicines

    If customers shift to medicines taken by other routes or to treatments requiring fewer injections, demand for West’s packaging and delivery products could fall.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  2. Customer concentration

    The ten largest customers generated 47.6% of 2025 sales, and one customer accounted for 15.8%. A loss of a major customer or fewer orders could materially affect results.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  3. Supply interruptions and input costs

    Some important raw materials come from single suppliers, and prices for materials and energy can change. Shortages or costs West cannot pass on to customers could disrupt production or reduce profits.

    From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K

  4. Manufacturing disruption

    Damage, outages, quality problems, or other events could interrupt production, especially where a product is made at only a few sites, and affect sales and customer relationships.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  5. Competition and pricing pressure

    Customers and competitors put pressure on prices. If West cannot offset this through its services, efficiency, or lower costs, its sales or profitability may suffer.

    From the company's own filingsWould hit how much of each sale it keeps2025 Form 10-K

  6. Product approvals and development

    New products can take years to develop and may need regulatory approval and customer acceptance. Delays or failure to commercialize them could limit future sales.

    From the company's own filingsWould hit how fast sales grow2025 Form 10-K

  7. Management said Q4 could be lumpy and implied only 6–7% organic growth.

    From our researchWould hit how fast sales growWST Q3 2026 earnings call transcript

  8. Operating margin was only 15.3% in Q1 2025 and 19.5% in Q4 2025 (supplied actuals), so 25% has been sustained only briefly.

    From our researchWould hit how much of each sale it keepsWST Q1 2026 earnings release

Is it a good business?

From 2016 to 2025 it earned between 14% and 34% on the capital invested in it, a median of 19%. Its cost of capital in the latest valuation is 9.8%; returns were above it in every one of the 10 years.

From 2016 to 2025 it earned between 12% and 28% on its shareholders' equity, a median of 17%.

Over 10 years its operating margin ranged from 13¢ to 27¢ per sales dollar, a median of 19¢. Gross margin ran from 32¢ to 42¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital18%
20162025

Cost of capital 9.8%

Return on equity16%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 18%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 2.5% in a year, so each remaining share owns a slightly bigger slice.

It holds $252.3M more in cash than it owes.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $417.80. Our put its value between $81.13 and $164.43, with $120.66 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $81.13

This scenario assumes West's sales boom of 2026 fades quickly and the business returns to slow growth of a few percent a year, with profits slipping back toward 2025 levels after the sale of one product line.

Base case, $120.66

This scenario assumes West keeps growing at a healthy mid-to-high single-digit pace after a very strong 2026, while holding on to most of its recent gains in profitability as higher-value drug packaging becomes a bigger share of sales.

Bull case, $164.43

This scenario assumes the strong demand that pushed West's sales up by double digits in 2026 lasts for several more years, and that its shift toward premium drug-packaging products keeps lifting profitability above anything it has earned before.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 246%

For West Pharmaceutical Services to be worth today's $417.80, sales would need to grow about 39.2% a year. We assume 5.9%. Over the last 5 years, sales grew 4.8% a year.

−10%0%+10%+20%+30%+40%+50%Past 5 yrs 4.8%We assume 5.9%Price needs 39.2%

Or, if sales grow 5.9% as we assume, the price works with a profit margin of 88.4% (we assume 25.0%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 39.2% a year?

Try your own numbers

We're moderately sure of this range: it scores 66 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $120.66 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average5.9%
  • Operating margin25.0%
  • Long-term growth rate3.0%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$120.66 -71.1%

Build